Request Legal Help Now - Free
LAWSUITS NEWS & LEGAL INFORMATION

Benicar Legal News Articles & Interviews

View Lawyer Interviews only

Respected Consumer Advocate Public Citizen wants Benicar Banned

Respected Consumer Advocate Public Citizen wants Benicar Banned November 18, 2017. By Gordon Gibb.
Santa Cruz, CA: Prospective plaintiffs who did not make it into the $300 million Benicar settlement and concerned about the capacity for filing a Benicar lawsuit going forward will be cheered by the latest petition to the US Food and Drug Administration (FDA) by the consumer advocacy group Public Citizen.
Read [ Respected Consumer Advocate Public Citizen wants Benicar Banned ]

Left Behind in Benicar Lawsuit Settlement

Left Behind in Benicar Lawsuit Settlement November 1, 2017. By Anne Wallace.
Camden, NJ: Daiichi Sankyo’s recent $300 million Benicar lawsuit settlement will end the story for some who were hurt by the blood pressure drug. But it will leave others out in the cold.
Read [ Left Behind in Benicar Lawsuit Settlement ]

Benicar Settlement Will Have No Material Financial Impact to Daiichi Sankyo

Benicar Settlement Will Have No Material Financial Impact to Daiichi Sankyo September 17, 2017. By Gordon Gibb.
New York, NY: It appears as if the recent announcement that Benicar manufacturer Daiichi Sankyo will make available $300 million to settle claims over Benicar side effects will not prove to be a hardship for the Japanese drug maker. The Reuters news agency (08/01/17) reported last month that according to a statement from Daiichi Sankyo, the settlement is expected to be funded by a collective of insurance companies underwriting Daiichi’s liabilities. As such, Daiichi Sankyo said the settlement would not have a material impact on its financial position.
Read [ Benicar Settlement Will Have No Material Financial Impact to Daiichi Sankyo ]

Are Benicar Generics Flying Under the Radar?

Are Benicar Generics Flying Under the Radar? September 4, 2017. By Anne Wallace.
Santa Cruz, CA:Drug maker Daiichi Sankyo has now offered $300 million to settle more than 2,000 Benicar lawsuits based on allegations that blood pressure medications, Benicar, Benicar HCT, Azor, and Tribenzor caused serious gastrointestinal injuries. But Mylan Pharmaceuticals Inc., Apotex, Inc., Lupin Pharmaceuticals Inc. and Ascend Laboratories LLC are in various stages of marketing generic Benicar in the US. A Canadian version of Daichi Sankyo’s Benicar, sold under the name Olmetec, is also available to Americans who manage to do their prescription shopping over the border. Cost-conscious consumers may miss out on information about Benicar side effects when they buy essentially the same drug under another name.
Read [ Are Benicar Generics Flying Under the Radar? ]

Deadline Set in $300 Million Settlement in Benicar Lawsuit – Short Window!

Deadline Set in $300 Million Settlement in Benicar Lawsuit – Short Window! August 10, 2017. By Brenda Craig.
Houston, TX Users of the blood pressure medication Benicar will receive an estimated average payout of $100,000 each in a settlement deal reached with Diiachi Sankyo and Forest Laboratories. The company admits no liability but agreed to pay compensation plaintiffs to some individuals who experienced gastrointestinal problems after using the medication.
Read [ Deadline Set in $300 Million Settlement in Benicar Lawsuit – Short Window! ]

Inside the $300 Million Benicar Settlement

Inside the $300 Million Benicar Settlement August 5, 2017. By Gordon Gibb.
Camden, NJ: When the manufacturers and marketers of Benicar agreed to the $300 million settlement to resolve state and federal Benicar lawsuits, they did so while admitting no liability for any wrongdoing, and maintaining their position that claims have no merit.
Read [ Inside the $300 Million Benicar Settlement ]

$300M Benicar Settlement Reached

$300M Benicar Settlement Reached August 3, 2017. By Lucy Campbell.

Santa Clara, CA: The makers of the controversial blood pressure medication, Benicar, have agreed a $300 million settlement potentially ending multi-district litigation (MDL) that claims the drug caused gastrointestinal injuries. Forest Laboratories Inc., and Daiichi Sankyo Inc., and about 2,300 plaintiffs in the MDL reached the agreement earlier this week. The settlement addresses claims filed collectively in state and federal court. The plaintiffs alleged personal injury stemming from defective design of Benicar (known generically as olmesartan), which is also in blood pressure products Benicar HCT, Azor and Tribenzor.

Read [ $300M Benicar Settlement Reached ]

One Defendant Dismissed from Benicar Lawsuit, Daiichi Sankyo Remains

One Defendant Dismissed from Benicar Lawsuit, Daiichi Sankyo Remains June 16, 2017. By Gordon Gibb.
Trenton, NJ: A Benicar lawsuit alleging Benicar side effects has been disentangled from one if its defendants after a doctor was summarily dismissed from the lawsuit on grounds that his inclusion in the lawsuit was without merit.
Read [ One Defendant Dismissed from Benicar Lawsuit, Daiichi Sankyo Remains ]

Benicar Illness and Weight Loss Lawsuit Witnesses Must Produce Records

Benicar Illness and Weight Loss Lawsuit Witnesses Must Produce Records May 7, 2017. By Gordon Gibb.
Camden, NJ: This spring has seen some developments in the Benicar side effects multidistrict litigation over gastrointestinal issues and sprue-like enteropathy associated with olmesartan (Benicar), a medication prescribed for high blood pressure. By the middle of March there were some 1,800 Benicar cases housed in the Benicar MDL in New Jersey.
Read [ Benicar Illness and Weight Loss Lawsuit Witnesses Must Produce Records ]

Revenues Drop While Lawsuits Rise over Benicar for Daiichi Sankyo

Revenues Drop While Lawsuits Rise over Benicar for Daiichi Sankyo March 6, 2017. By Gordon Gibb.
Parsippany, NJ: This could evolve to a compelling year for Japanese-based pharmaceutical giant Daiichi Sankyo following the expiry of its patent exclusivity for Benicar last year and a corresponding drop in revenue for a product characterized as its global mainstay. As generics for olmesartan (Benicar) continue to gain market share in 2017, coupled with a growing number of Benicar lawsuits which number around 1,700 and climbing, industry watchers will be monitoring Daiichi in the coming months and years to see how the corporation responds, and what effect that may have on consumers.
Read [ Revenues Drop While Lawsuits Rise over Benicar for Daiichi Sankyo ]

Request Legal Help Now! - Free